C
CereGate
Germany · Healthtech
Clinical-stage neurotechnology company developing software-based therapies through existing stimulation implants.
Product
CereGate develops a computer-brain interface platform for neurological therapies. Its software runs on existing deep-brain stimulation systems, with clinical work initially focused on freezing of gait in people with Parkinson’s disease.
The Munich company aims to use new stimulation approaches to address walking interruptions that can persist despite medication and conventional stimulation. Its technology is in clinical investigation; the company also conducts research in spinal cord stimulation. Matthias Puls leads CereGate as chief executive.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series C | Undisclosed | Impact Ventures (Hungary) — Participant |